Pharmaceuticals & Biopharmaceuticals

West Chester, Ohio – September 25, 2026 -- E Tech Group will present on the compliance and data integrity risks of scaling laboratory automation from pilot to full production at the ISPE Boston Area Chapter 2026 Product Show on October 7 at Gillette Stadium in Foxborough, Massachusetts.

Session targets the gap between pilot success and regulated production failure

Sura Hadi, Director of Laboratory Automation and Industrial Robotics (LAIR) at E Tech Group, will lead the 3:00 p.m. ET session, "From Pilot to Production: Scaling Lab Automation Without Breaking Compliance, Data Integrity, or Teams," in West Red Level, Suite 81. The talk addresses why automation pilots that succeed in contained workflows frequently break down when expanded into regulated manufacturing environments, where instruments must connect to scheduling systems, Laboratory Information Management Systems (LIMS), Electronic Laboratory Notebooks (ELN), and other enterprise platforms.

Shanghai – September 25, 2026 -- Sanyou Biopharmaceuticals Co., Ltd. and NovoCodex Biopharmaceuticals Co., Ltd. have signed a strategic collaboration agreement to jointly develop next-generation antibody-drug conjugates (ADCs), combining Sanyou Bio's AI-driven antibody discovery platforms with NovoCodex's clinically validated site-specific conjugation technology.

NovoCodex brings a clinically validated conjugation platform to the partnership

NovoCodex's proprietary NovoCodeTM platform incorporates unnatural amino acids into antibodies to achieve defined, controllable conjugation sites, producing homogeneous ADC products rather than the heterogeneous mixtures typical of traditional random conjugation. The technology has been validated in the pivotal Phase III trial of ARX788 and supported ARX305 in showing a favorable safety window and durable antitumor activity in advanced renal cancer patients with high CD70 expression.

Pleasanton, Calif. – – September 25, 2026 -- Aqua Medical, Inc. has closed a Series B financing round led by Nashville-based Relevance Ventures, with proceeds earmarked to complete its ongoing U.S. RESTORE-1 pilot study and prepare for a planned U.S. pivotal trial of its investigational diabetes procedure.

Series B capital targets completion of RESTORE-1 pilot and pivotal trial launch

The financing will fund the remaining stages of the RESTORE-1 pilot study, which is evaluating Aqua Medical's Proximal Intestinal Mucosal Ablation (PIMA) procedure for Type 2 diabetes under an FDA-approved Investigational Device Exemption. The company said the round will also support operational preparations, including patient recruitment infrastructure, for a larger planned pivotal trial subject to regulatory authorization.

Seattle – September 25, 2026 -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that President and CEO Steven Quay, M.D., Ph.D., will serve as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), scheduled for October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston.

Quay joins regulatory and academic leaders to discuss clinical pathways for aging-related diseases

The panel, titled "Clinical Trials in Diseases of Aging: From Evidence to New Therapeutics and Regulatory Pathways," is set for Thursday, September 25, 2026, from 11:20 a.m. to 12:00 p.m. ET. The session will be moderated by Sebastien Thuault, Editor at Nature Medicine, and will include Jill Lee, Director of Regulatory Policy & Intelligence at Novo Nordisk; Calum MacRae, Professor at Mass General Brigham; and Steve Horvath, Professor at UCLA.

Philadelphia and Boston – September 25, 2026 -- Minaris, a global cell and gene therapy CDMO, has partnered with synthetic biology firm Asimov to integrate proprietary OXGENE viral vector technology into Asimov's AAV Edge producer cell lines, targeting higher manufacturing titers and improved product quality for adeno-associated virus (AAV) gene therapies.

Stable production systems aim to replace costly transient manufacturing

Most AAV programs currently rely on transient production, requiring multiple GMP plasmids to be transfected for every batch. This method drives up costs, limits scalability, and can produce inconsistent product quality. Stable production systems have historically been difficult to develop due to the complexity and interdependency of viral genetics involved.

London and Boston – September 25, 2026 -- Basecamp Research has closed a $140 million oversubscribed Series C financing to train new EDEN foundation models and push a pipeline of AI-designed therapeutics toward clinical development.

S32 leads a syndicate spanning NVIDIA, Anthropic-adjacent backers and sovereign funds

The round was led by S32, with participation from NVIDIA, Menlo Ventures' Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, joins Basecamp's Board of Directors.

Dover, Del. – September 25, 2026 -- Clywedog Therapeutics, Inc. reported that its investigational menin inhibitor balomenib produced a placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p0.01) and 0.70% at Week 16 (p0.05) in a Phase 1b trial, effects recorded three months after the drug's final dose following just three weeks of treatment.

North Bethesda, Md. – September 24, 2026 -- The International Society for Pharmaceutical Engineering (ISPE) will convene its 2026 Annual Meeting & Expo in Washington, D.C. from October 18-21, drawing pharmaceutical manufacturing leaders for four days of hybrid sessions combining in-person and virtual attendance.

Lonza and Eli Lilly executives headline keynote lineup on manufacturing innovation

Wolfgang Wienand, PhD, CEO of Lonza, will present "The Lonza Engine: Manufacturing the Medicines of Tomorrow," while Kevin Trivett, Senior Vice President of Device and Packaging Operations Manufacturing at Eli Lilly and Company, delivers "Lilly: Embracing Technology to Reach Patients." Additional featured speakers include Marla Phillips, PhD, CEO and President of Pathway for Patient Health LLC, addressing AI and human oversight in manufacturing loops, and cancer survivor and research advocate Jamie Valvano.

Stockholm – September 24, 2026 -- Sobi (STO: SOBI) will present new clinical data on its rare-disease drug Gamifant (emapalumab) at the 2026 Annual Meeting of the Histiocyte Society (HS2026), running September 26-29 in Rotterdam, the Netherlands, with a pooled survival analysis nominated for the meeting's top poster prize.

Pooled transplant-survival analysis earns Robert J. Arceci Prize nomination

The accepted abstract set includes a new pooled analysis of pre- and post-transplant survival outcomes in primary haemophagocytic lymphohistiocytosis (HLH), drawing on data across three prospective trials. Sobi said the analysis was selected as one of the ten highest-scoring poster abstracts at HS2026 and has been nominated for the Robert J. Arceci Prize for Best Poster.

Barcelona – September 24, 2026 -- Daewoong Pharmaceutical has completed enrollment of 104 idiopathic pulmonary fibrosis (IPF) patients in its global Phase 2 trial of Bersiporocin (DWN12088), with top-line results now expected in the first half of 2027.

Trial spans South Korea and the US with balanced enrollment

Of the 104 patients, 55 (52.9%) were enrolled in South Korea and 49 (47.1%) in the United States. The company presented full baseline patient characteristics at the European Respiratory Society (ERS) Congress 2026 in Barcelona on September 6, following interim data shared earlier at KATRDIC 2025.